CTX Alliance

Cancer Therapeutics CRC (CTx) is an Australian drug discovery and development company that operates as a collaborative alliance between major research institutes and commercial partners. The company focuses on translating high-quality academic research into clinical-stage oncology assets through a sophisticated small molecule discovery engine. CTx has successfully licensed multiple programs to global pharmaceutical leaders, including significant deals with Merck & Co. (MSD), Amgen, and Pfizer. Its business model leverages a network of expertise to advance novel targets in epigenetics and cell signaling from early discovery through to Phase 1/2 clinical trials.